ArticleJournal of cardiothoracic surgery2026
Network pharmacology and experimental evaluation of Sanwei Tanxiang Tangsan in doxorubicin-induced heart failure.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Network pharmacology and experimental evaluation of Sanwei Tanxiang Tangsan in doxorubicin-induced heart failure.Journal of cardiothoracic surgery · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundHeart failure (HF) is a complex syndrome characterized by inflammation, oxidative stress, and cardiomyocyte apoptosis, for which effective and well-tolerated therapies remain limited. This study sought to explore the potential mechanisms by which Mongolian medicine Sanwei Tanxiang Tangsan (STX) may be associated with AKT1/p53-related signaling in the mitigation of HF, employing network pharmacology, molecular docking, and animal experimentation. MATERIALS AND
methodsActive constituents and corresponding targets of Mongolian medicine STX were systematically screened, followed by the construction of drug-disease interaction networks to identify pivotal proteins and pathways. A doxorubicin-induced HF rat model was established, and after four weeks of intragastric administration of Mongolian medicine STX and sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor, positive control), cardiac functional parameters and expression levels of AKT protein 1 (AKT1), interleukin-6 (IL-6), and p53 were assessed.
resultNineteen active components were identified in Mongolian medicine STX, interacting with 153 HF-associated targets, among which AKT1, IL-6, and TP53 served as the core genes. Molecular docking analysis revealed that quercetin and luteolin possessed moderate predicted binding affinities and stable interactions with the corresponding targets. Animal experiments indicated that Mongolian medicine STX significantly reduced N-terminal pro-brain natriuretic peptide levels and altered myocardial AKT1, IL-6, and p53 protein abundance. However, echocardiographic parameters showed no statistically significant improvement compared with the Model group.
conclusionMongolian medicine STX may exert cardioprotective effects in HF, as reflected by improvements in biochemical and histopathological indicators, and these effects may be associated with AKT1/p53-related signaling pathways. However, direct pathway activation and causal mechanisms were not confirmed in the present study and require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.